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Abstract
Objective: To assess the safety of meningococcal group B (MenB)-4C vaccine.
Participants: Undergraduates, dormitory residents, and persons with high-risk medical 
conditions received the MenB-4C vaccine two-dose series during mass vaccination clinics from 
12/2013 through 11/2014.
Methods: Adverse events (AEs) were identified by 15 minutes of observation postvaccination, 
spontaneous reports, surveys, and hospital surveillance. Causality was assessed for serious adverse 
events (SAEs).
Results: 16,974 persons received 31,313 MenB-4C doses. The incidence of syncope during the 
15-minutes post-dose 1 was 0.88/1000 persons. 2% of participants spontaneously reported an AE 
(most common were arm pain and fever). 3 SAEs were suspected of being caused by the vaccine, 
including one case of anaphylaxis.
Conclusions: Most AEs reported were nonserious and consistent with previous clinical trial 
findings. Measures to prevent injury from syncope and to treat anaphylaxis should be available 
wherever vaccines are administered. Our safety evaluation supports the use of MenB-4C in 
response to outbreaks.
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Introduction
Neisseria meningitidis can cause meningitis or sepsis, either of which can be fatal or result 
in long-term disability.1 N. meningitidis serogroups A, B, C, W, and Y are the most common 
causes of meningococcal disease. Vaccines to prevent infections by serogroups A, C, W, and 
Y have been recommended for adolescents in the United States since 2005.2 The first 
meningococcal serogroup B (MenB) vaccine was approved in the United States in October 
2014.
Meningococcal infections occur sporadically or as outbreaks. There were MenB outbreaks at 
seven US universities between 2008 and 2015.3 Two US universities experienced unrelated 
MenB outbreaks in 2013. Between March 2013 and March 2014, there were nine cases 
among persons linked to University A in New Jersey.4 At University B in California, there 
were five cases among students between March and November 2013. Each university 
worked with their state and local public health authorities to provide antibiotic prophylaxis 
to close contacts of the MenB case-patients and launched health education campaigns in an 
attempt to prevent further cases. When these two outbreaks were identified, a MenB vaccine 
was not yet licensed in the US, but had already been studied in phase 3 clinical trials. The 
Centers for Disease Control and Prevention (CDC) received permission from the Food and 
Drug Administration (FDA) to sponsor mass vaccination campaigns using the four-
component MenB vaccine (MenB-4C; Bexsero, Novartis Vaccines) at each university under 
an expanded access investigational new drug (IND) protocol. The purpose of the IND was to 
provide access to the vaccine to persons at increased risk of meningococcal disease because 
of these outbreaks, not to establish the efficacy or safety of the vaccine. However, vaccine 
safety monitoring was required under the IND, and we describe the results of the safety 
monitoring here.
Methods
Vaccination
Persons associated with each university who were determined to be at increased risk of 
MenB disease due to the outbreaks were eligible to receive vaccine, which included: all 
undergraduate students; anyone residing in a dormitory; and students, faculty, and staff with 
a medical condition that increases the risk of meningococcal disease (eg functional or 
anatomic asplenia, complement pathway deficiencies). The protocol was approved by the 
CDC institutional review board. Written informed consent was obtained from all participants 
≥18 years old, and parental consent and written assent were obtained for participants <18 
years. Vaccination costs were covered by each university; vaccine was offered free of charge 
to eligible individuals.
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MenB-4C vaccine is a two-dose series with the doses administered at least 1 month apart via 
intramuscular injection into the deltoid muscle. MenB-4C was supplied in a prefilled 
syringe, the tip cap of which may contain natural rubber latex. The vaccine may contain less 
than 0.01 micrograms of kanamycin, which is an aminoglycoside antibiotic used in the 
manufacturing process.
Each university held mass vaccination clinics in a multipurpose room over 4- to 10-day 
periods. Up to 25 nurses administered as many as 2,000 doses per 8 hour day. A screened-off 
area with cots and limited medical supplies was set up for the use of a physician and nurse 
who were present to evaluate and treat any participant who might experience an adverse 
event (AE). Additional catch-up vaccination dates were offered for smaller numbers of 
individuals. Vaccines were administered at University A from December 2013 through 
November 2014 and at University B from February 2014 through June 2014.
Each participant completed a written questionnaire prior to vaccination to screen for 
potential contraindications or precautions to receiving MenB-4C, including hypersensitivity 
to vaccine components or latex, and also for conditions in which this vaccine had not been 
previously studied (those with chronic medical conditions or who were pregnant, 
breastfeeding, or aged >50 years). Persons who screened positive were interviewed by 
medical staff to determine whether vaccination could proceed or should be deferred pending 
additional information. In an effort to prevent postinjection syncope, participants were asked 
if they had a history of fainting with injections and were offered the opportunity to receive 
the injection lying down instead of seated. At University A, fainting history was assessed 
verbally by staff performing the injection; at University B, a written question was added to 
the screening questionnaire.
Vaccine safety monitoring
An AE was defined as any untoward medical occurrence associated with the use of the 
vaccine, whether or not it was considered to be caused by the vaccine. A serious adverse 
event (SAE) was any AE that resulted in death, a life-threatening event, hospitalization, a 
persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions, or a congenital anomaly/birth defect.5 To determine whether each SAE was 
suspected of being caused by the vaccine, we performed individual-level causality 
assessment.6
We identified AEs using active and passive methods. Clinic staff observed vaccinees in a 
seating area for 15 minutes post vaccination. We instructed participants to report anything 
that they considered to be a serious side effect to a dedicated phone number, which was 
answered 24 hours a day. Both universities had on-campus student health clinics where 
providers documented any visit by a participant in which either the patient or provider 
suspected an AE might be related to MenB-4C. When participants came to receive dose 2, 
they were required to complete a written questionnaire intended to solicit potential SAEs. 
We sent emails to participants 30 days following dose 2 (and to those who only received 
dose 1) requesting that they complete an online version of the same questionnaire regarding 
events that had occurred since the last dose. The health service at each university 
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communicated with local hospitals to document emergency department visits and inpatient 
admissions following vaccination among students.
Analysis
We coded AEs and categorized SAEs using the medical dictionary for regulatory activities 
(MedDRA) version18. Each diagnosis or symptom was assigned to one MedDRA “Preferred 
Term.” If a diagnosis was reported, then associated symptoms were not coded. Rates were 
calculated by dividing the number of AEs by the number of persons vaccinated or the 
person-time under surveillance as appropriate. Statistics were calculated using SAS9.3 and 
OpenEpi.7
Results
University A had 6,556 undergraduates eligible for vaccination (representing 5 class years) 
of whom 98% received the first dose and 93% the second dose, for a series completion rate 
of 93%. There were 835 eligible graduate students. University B had 19,257 undergraduates 
(representing 4 class years) of whom 51% received the first dose and 40% the second dose, 
for a series completion rate of 78%. Very few graduate students were eligible for 
vaccination. For the two universities combined, there were 16,974 participants vaccinated 
with at least one dose and 31,313 total MenB-4C doses administered (Table 1).
Screening
Prior to dose one, 7% screened positive for potential contraindications or precautions at 
University A and 8.4% at University B (excluding the additional question about fainting 
history) (Table 2). History of latex sensitivity was reported by 116 participants, but upon 
interview, only 9 (0.05% of participants screened) described a history consistent with a true 
hypersensitivity reaction. All 9 were asked to either provide medical documentation or 
consult with an allergist prior to vaccination, but 8 were lost to follow-up despite attempts to 
contact them. A possible aminoglycoside allergy led to deferral in only 1 participant. Two 
participants thought they might be pregnant, but both subsequently had a negative pregnancy 
test prior to vaccination. Overall, after interview by medical staff, only 20 (0.1% of all 
participants) were not allowed to be vaccinated immediately, and ultimately only 1 
participant was determined after receipt of medical history documentation to have a true 
contraindication to receiving the vaccine (a severe latex allergy).
All adverse events
At University A, we collected 754 AE reports regarding 640 unique individuals, and at 
University B, we collected 964 AE reports regarding 784 unique individuals (Table 3). For 
both universities combined an AE was recorded for 8.4% of vaccinated individuals. The AEs 
corresponded to 292 different MedDRA Preferred Terms (ie distinct types of events). 
Overall, the most commonly reported AEs were pain in the injected arm (10%), fever (9%), 
headache (5%), nausea (4%), and fatigue (4%).
There were 114 AEs during the 15-minute observation period; the most common were 
presyncope (56%), syncope (15%), dizziness (6%), nausea (4%), and anxiety (3%). Two 
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participants were treated for pruritus with oral antihistamines. One had localized pruritus of 
the anterior neck. The other developed generalized pruritus 4 hours after the first dose and 
began having itching on the back within 15 minutes of the second dose. There were no SAEs 
during the 15 minutes.
Only 2% of vaccinated individuals spontaneously reported a concern or sought medical care 
or advice for an AE by calling the phone line or making a clinic visit. Phone calls most 
commonly concerned fever (14%), pain in the injected arm (10%), chills (8%), headache 
(7%), nausea (6%), fatigue (5%), dizziness (5%), and myalgia (5%). 17% of all phone calls 
were regarding injection site reactions alone. At University A, half of the phone calls 
occurred on postvaccination days 0 and 1, and 90% by day 9 (range 0–130); at University B, 
half of the phone calls occurred on postvaccination days 0 and 1, and 90% by day 6 (range 
0–27). The most common AEs recorded during clinic visits were pain in the injected arm 
(13%), fever (8%), headache (8%), sore throat (6%), fatigue (5%), nausea (5%), myalgia 
(4%), dizziness (3%), and neck pain (3%). Among all clinic visit AEs, 21% were injection 
site reactions alone. At University A, half of the clinic visits occurred on postvaccination 
days 0 and 1, and 90% by day 8 (range 0–59); at University B, half of the clinic visits 
occurred by postvaccination day 4, and 90% by day 17 (range 0–59). The types of AEs 
reported by phone and clinic visits were similar following both doses.
The AE questionnaire administered in person prior to dose 2 and online following dose 2 (or 
following dose 1 for those who received only one dose) asked participants to report AEs 
regardless of whether or not they believed the AE was caused by the vaccine. The two most 
common AEs identified by this method were pain in the injected arm (10%) and fever (8%), 
but the third most common was emergency room visits for alcohol poisoning (3%). Injuries 
from accidents and sports accounted for 10% of AEs reported on the questionnaires. There 
were no AEs associated with pregnancy. Eight participants became pregnant following 
vaccination, but all had elective abortions for reasons unrelated to vaccination.
Serious adverse events
Among all persons vaccinated, 54 (0.3%) experienced an SAE (University A, n = 27; 
University B, n = 27). These included 52 hospitalizations, 1 death, and 1 potentially life-
threatening event. The death was an accidental drowning that occurred 27 days post dose 1 
and was not related to vaccination. The most common category of SAE was “infections and 
infestations” (n = 16), which includes appendicitis, the single most common diagnosis 
among SAEs (n = 8) (Table 4). Seven appendicitis cases occurred following dose 1 
(symptom onset ranged from 0 to 54 days postvaccination). The eighth case had onset 14 
days after dose 2. The incidence of appendicitis during the safety monitoring period among 
persons vaccinated was 1.14 per 1000 person-years. This is similar to the baseline incidence 
rate in the United States of 1.53/1000 person-years for ages 10–19 years and 1.30/1000 for 
ages 20–29 years.8
The second most common category of SAE was “psychiatric disorders” (n = 13). 11 of these 
cases were identified at University B, which routinely tracked mental health hospital 
admissions among its undergraduate students. The incidence of mental health 
hospitalizations at University B among vaccinated persons was 2.75 per 1000 person-years, 
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which was lower than the baseline rate of 4.48 per 1000 person-years during the calendar 
year prior to the start of the MenB-4C vaccination program. The distribution of the 
diagnoses for these cases was also similar to base-line (data not shown).
Only three SAEs were suspected of being caused by MenB-4C vaccine. First was a case of 
rhabdomyolysis requiring hospitalization in a 20-year-old male following dose 2. He lifted 
weights soon after vaccination and developed myalgia and fever later that day. The myalgia 
was in the shoulders and back and increased over the next 2 days after which his serum 
creatine phosphokinase was found to be elevated. Vaccination is unlikely to be a sufficient 
cause of rhabdomyolysis, but based on the timing it may have been a contributory factor, so 
the AE was considered to be possibly related to vaccination. Second was a case of 
anaphylaxis in a 22-year-old female. She developed swelling in her throat and face 30 
minutes following dose 1. She was treated in the clinic and emergency room with quick 
resolution of symptoms. Of note, she had hives on her trunk during the 2 days prior to 
vaccination, which may have been related to a topical medication for skin infection. This AE 
was classified as serious because it may have progressed to a life-threatening condition if the 
participant had not been evaluated and treated promptly. Third was an 18-year-old male 
participant who developed fever, myalgia, malaise, and neck stiffness approximately 7 hours 
following dose 1. Tests for infectious diseases, including lumbar puncture, were negative, 
but he was hospitalized for 1 day and treated empirically with antibiotics. His symptoms 
resolved within 24 hours. This event was determined to be possibly related to vaccination 
based on the timing of symptom onset and the absence of an identified alternative cause.
Urticaria and rash
Few participants reported events that could potentially represent hypersensitivity reactions. 
Urticaria was reported by 61 (0.4%) participants, but only 6 made a clinic visit and 7 a 
phone call regarding the urticaria. Three participants reported injection site urticaria after 
dose 1, but all received dose 2 without any additional AEs reported. Urticaria that began on 
postvaccination days 0 or 1 was reported by 18 (0.1%) participants. These events are not 
necessarily vaccine related, but are more likely to be so than urticaria with later onset.9 
Nonurticarial rashes were reported by 86 (0.5%) participants (22 injection site rash and 64 at 
other body sites); 16 involved a clinic visit and 26 made phone calls. No one reported a rash 
after both doses. Most (77%) injection site rash reports were not medically attended and the 
descriptions given did not always clearly differentiate from injection site erythema. Only one 
dermatologic condition was considered clinically significant: a 19-year-old female 
developed a persistent papular rash on her extremities 1 day following dose 2. She had 
multiple medical visits and a skin biopsy diagnosed leukocytoclastic vasculitis, which 
resolved with oral corticosteroids. The causality assessment was indeterminate.
Syncope and presyncope
Syncope and presyncope occurred most commonly during the 15-minute observation period, 
though in some cases it occurred later (Table 5). Syncope cases occurred throughout the 15-
minute observation period, not all were at the time of injection. The incidence of syncope 
during the 15-minute observation period following dose 1 was higher for women (1.45 per 
1,000) than for men (0.38 per 1,000), p = 0.02. Presyncope also occurred more frequently in 
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women (4.69 versus 3.20 per 1,000), p = 0.08. Two participants sustained minor lacerations 
after falling, and another participant fell from a standing position and hit his head resulting 
in an emergency room evaluation but no injuries. Persons who had syncope or pre-syncope 
following dose 1 were no less likely to receive dose 2 than those who did not (p = 0.30). 
Only one person had syncope after both doses.
At University B, 5% of participants reported a history of fainting on the pre-dose 1 
screening. During the 15-minute observation period, the occurrence of syncope among those 
who reported a history of fainting [n = 1 (0.20%)] was not significantly greater than those 
without such a history [n = 7 (0.07%)], p = 0.67, whereas the occurrence of presyncope was 
significantly greater for those with a fainting history [n = 13 (2.61%)] compared to those 
without [n = 32 (0.34%)], p < 0.0001. Screening did not identify everyone who would 
experience postvaccination syncope or presyncope. Among cases that occurred during the 
15-minute observation period, 74% had not reported a history of fainting. Specifically 
among those with syncope, 87% had not reported a history of fainting. The relative risk of 
syncope at University B compared to University A controlling for sex was 0.65 (95%CI: 
0.23, 1.78) and of presyncope was 1.51 (95%CI:0.89, 2.54).
Comment
During large vaccination campaigns with MenB-4C at two US universities in which 
vaccinated persons were given multiple opportunities and methods to report AEs following 
vaccination, 8% reported an AE, of which 96% were not serious. The most common AEs 
reported were fever and pain in the injected arm, which were expected based on the clinical 
trials of this vaccine.10–13 Anecdotally, many more vaccinees experienced pain in the 
injected arm than who reported it. Participants were not required to report every nonserious 
symptom, and not all felt the need to seek care or advice for these milder types of reactions. 
The anticipatory guidance provided about the expected types and severity of adverse 
reactions may have reduced the number of individuals who sought medical care or advice. 
Our results indicate the amount of health care utilization to expect for a mass vaccination 
campaign using MenB-4C; 2% of vaccine recipients called or visited the clinic for an AE, 
mostly within the first week postvaccination.
It should be kept in mind that not all AEs that occur after vaccination are caused by the 
vaccine. For some events, the timing is coincidental. We did not perform individual level 
causality assessment for all the nonserious AEs reported, however some clinic visits were 
for events such as pharyngitis and upper respiratory tract infection, which were most likely 
not related to vaccination. Individual-level causality assessment was done for all SAEs, and 
only 3 were even suspected of being caused by the vaccine. All three of these participants 
recovered with no long-term sequelae. One participant had an anaphylactic reaction, which 
quickly resolved with outpatient treatment. Anaphylaxis is possible with any type of 
vaccine, but is rare, occurring in about 1 per million vaccine doses.14 This is the only known 
case of anaphylaxis following MenB-4C reported to date. Too few doses have been given to 
date to know whether MenB-4C might be associated with a different rate of anaphylaxis 
than other vaccines.
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Causality assessment can also be evaluated at the population level by looking at the observed 
incidence rate of an AE and comparing it to the background rate in the population expected 
to occur by chance alone. Appendicitis was the most common diagnosis among SAEs. 
While these cases were not suspected of being caused by vaccine at the individual level, the 
lack of association with vaccine is supported by the population level assessment, which 
found the observed rate to be similar to the expected rate. The vast majority of vaccine 
recipients were aged 18–22, and appendicitis is a relatively common condition in this age 
group. There were only single cases of most other types of SAEs, so comparison to 
background rates was not performed for those.
AE monitoring was required because these vaccination programs were conducted under an 
IND. Now that MenB vaccines are licensed in the United States, colleges or other 
organizations conducting MenB vaccination campaigns would not be required to conduct 
this type of extensive safety monitoring. However, observing patients for 15 minutes after 
vaccination in a seated or lying position is advised for all vaccines given by injection, 
regard-less of the setting of vaccination.15 This is because of concern for syncope. Syncope 
can result in injuries from falling, which can be serious.16 There are few publications 
reporting postvaccination syncope rates, and estimates vary by the age group studied and/or 
the method of ascertainment. The syncope rate we observed in this population of mostly 18–
22 year olds was lower than the rate in adolescent girls who received HPV vaccine in several 
US health care organizations but higher than in US military personnel.17,18 We observed a 
higher rate with the first dose in the series, suggesting that those who had syncope/
presyncope after dose 1 may have been more likely to take preventive measures for dose 2. 
Also of note is that the fainting history screening approach with a written questionnaire and 
medical consultation used at University B did not result in a lower rate of syncope following 
dose 1 compared to verbal screening by vaccine administrators used at University A. The 
screening did not identify most of the people who would go on to experience syncope or 
presyncope following dose 1, which reinforces the need for all persons being vaccinated to 
follow the Advisory Committee on Immunization Practices (ACIP) guidelines about 
postvaccination observation to prevent injuries.
Limitations
We did not require participants to report nonserious AEs, therefore the incidence of expected 
AEs such as pain in the injected arm or myalgia is likely underestimated. The online AE 
questionnaire sent following the last dose had a low response rate at both universities 
(≤51%). Other methods of reporting were available following both doses, so it is unlikely 
that any SAE a participant believed to possibly be vaccine-related went unreported. It was 
not possible to evaluate vaccine effectiveness in these vaccination programs, but no cases of 
MenB disease occurred in participants who received one or more doses of MenB-4C 
vaccine.
Conclusion
The ACIP currently recommends use of MenB vaccine during outbreaks and also for 
persons who are at increased risk for serogroup B meningococcal disease because of certain 
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risk factors.19 The ACIP also states that a MenB vaccine series may be administered to 
adolescents and young adults aged 16–23 years based on individual clinical decision 
making.20 Our vaccine safety evaluation identified no adverse reactions with lasting 
sequelae and supports the use of MenB-4C in response to outbreaks. A second MenB 
vaccine (Trumenba, Pfizer), which was not evaluated in this safety assessment, was also 
licensed in the United States after these two outbreaks. As with all vaccines, CDC and FDA 
will continue to monitor the safety of MenB vaccines now that they are licensed. Providers 
and patients in the United States are encouraged to report clinically significant AEs to the 
Vaccine Adverse Event Reporting System, even if unsure of whether the vaccine caused the 
AE.21
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Table 1.
Demographic characteristics and number of persons vaccinated with MenB-4C vaccine.
University A University B Combined
Doses administered
 Dose 1 7,143 9,831 16,974
 Dose 2 6,632 7,707 14,339
 Total doses 13,775 17,538 31,313
University affiliation
 Undergraduate students 6,437 9,800 16,237
 Graduate students 671 6 677
 Faculty/staff/other 35 25 60
Age in years, median (range) 20(16–65) 20(18–64) 20 (16–65)
Sex
 Male 3,713 4,247 7,960
 Female 3,400 5,553 8,953
 Unknown 30 31 61
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Table 2.
Number of persons answering “yes” on questionnaire administered prior to dose 1 to screen participants for 
potential contraindications or precautions to receiving MenB-4C vaccine.
Question University A
n (%)
University B
n (%)
Combined
n (%)
Are you aware of any severe reaction to any vaccine you have previously received that 
required medical attention? 36 (0.50%) 36 (0.37%) 72 (0.42%)
Do you have a known sensitivity to latex? 39 (0.55%) 77 (0.78%) 116 (0.68%)
Do you have a known allergy to kanamycin? (Kanamycin is an antibiotic similar to 
neomycin and streptomycin.) 4 (0.06%) 4 (0.04%) 8 (0.05%)
Do you have any known serious or chronic medical problems that we should be aware of? 420 (5.9%) 726 (7.38%) 1,146 (6.75%)
Are you older than 50 years? 6 (0.08%) 2 (0.02%) 8 (0.05%)
Are you pregnant or think you could be pregnant? 0 (0%) 2 (0.02%) 2(0.01%)
Are you breastfeeding? 0 (0%) 0 (0%) (0%)
Have you ever fainted or passed out after getting a vaccine, receiving an injection, or having 
your blood drawn?A
n/a 500 (5.08%) n/a
Note.
A
This question was not included on the written questionnaire at University A and no data was collected for the verbal fainting history screening 
conducted there.
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